Watson 667 (Divalproex sodium delayed release 500 mg)

Pill imprint Watson 667 has been identified as Divalproex sodium delayed release 500 mg.

Divalproex sodium is used in the treatment of bipolar disorder; mania; migraine prevention; epilepsy; borderline personality disorder (and more), and belongs to the drug class fatty acid derivative anticonvulsants. When treating epilepsy and manic episodes associated with bipolar disorder: There is positive evidence of human fetal risk during pregnancy. When treating migraine: Not for use in pregnancy. Divalproex sodium 500 mg is not a controlled substance under the Controlled Substance Act (CSA).

Divalproex sodium delayed release

Imprint:

Watson 667

Strength:

500 mg

Color:

Red

Shape:

Elliptical / Oval

Availability:

Prescription only

Drug Class:

Fatty acid derivative anticonvulsants

Pregnancy Category:

D - Positive evidence of risk - When treating epilepsy and manic episodes associated with bipolar disorder
X - Not for use in pregnancy - When treating migraine

CSA Schedule:

Not a controlled drug

Manufacturer:

Watson Laboratories, Inc.

National Drug Code (NDC):

62037-0667

Inactive Ingredients:

candelilla wax
cellacefate
silicon dioxide colloidal
croscarmellose sodium
dextrates
FD&C Red No. 40
hydroxypropyl cellulose
hypromellose 2910 (15 mPa.s)
ferrosoferric oxide
lactose monohydrate
magnesium stearate
microcrystalline cellulose
propylene glycol
silicon dioxide
titanium dioxide
triacetin
aluminum oxide

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.